PAREXEL Launches Expanded Genomic Research Services

London, February 17, 2016 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced expanded services and capabilities in genomic-based drug development. The PAREXEL® Genomic Medicine team offers clients a variety of strategic and operational genomic research services to accelerate drug development and to support regulatory and payer approval processes.Biopharmaceutical companies are increasingly applying genomics to drug discovery and development to better understand the genetic basis of disease, drug targets, and... Source: RealWire

Read More